Posted by Michael Wonder on 29 Mar 2022
Nurix Therapeutics awarded Innovation Passport for entry into Innovative Licensing and Access Pathway in the United Kingdom for NX-1607
29 March 2022 - NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumour types.
Nurix Therapeutics today announced that the UK MHRA has awarded the innovative medicine designation, the Innovation Passport, for NX-1607 in the treatment of patients with advanced solid tumours.
Nurix plans to present the initial pharmacokinetic and pharmacodynamic data from the NX-1607 Phase 1a study in mid-2022.
